INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 435m ago
HOUSE PTR35m ago
SEC 13F35m ago
ROBINHOOD CHAIN35m ago
SEC FORM 4/Option exerciseVerified dataRule 10b5-1 plan

Stein Steven H reported INCY

EVP & Chief Medical Officer · INCYTE CORP · Common Stock

Side
M
Value
$100K
Shares
1,044
Price
$95.76
Executed
Nov 5, 2025
Disclosed
Nov 7, 2025
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Nov 5 executedNov 7, 2025 disclosed

INCY · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
2/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+4 / 25

$100K reported value · 1.0% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · INCY

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    8
    HL
    Heeson LeeEVP, Head of Incyte Intl
    INCYINCYTE CORP
    Tax withholding
    		F$54K
    463 sh
    		Oct 1, 2026Oct 5, 2026
    traded Oct 1, 2026
    		+4dSEC FORM 4

    Evidence

    16
    GH
    Gardner David HEVP, Chief Strategy Officer
    INCYINCYTE CORP
    Tax withholding
    		F$117K
    920 sh
    		Sep 22, 2026Sep 24, 2026
    traded Sep 22, 2026
    		+2dSEC FORM 4

    Evidence

    12
    BK
    Basi Ramitpal KEVP, Human Resources
    INCYINCYTE CORP
    Tax withholding
    		F$65K
    504 sh
    		Aug 25, 2026Aug 27, 2026
    traded Aug 25, 2026
    		+2dSEC FORM 4

    Evidence

    0
    MA
    Mayes Patrick AEVP & Chief Scientific Officer
    INCYINCYTE CORP
    Option exercise · 10b5-1 plan
    		M$235K
    2,207 sh
    		Aug 5, 2026Aug 7, 2026
    traded Aug 5, 2026
    		+2dSEC FORM 4

    Evidence

    0
    MA
    Mayes Patrick AEVP & Chief Scientific Officer
    INCYINCYTE CORP
    Option exercise · 10b5-1 plan
    		M—
    2,207 sh
    		Aug 5, 2026Aug 7, 2026
    traded Aug 5, 2026
    		+2dSEC FORM 4

    Evidence

    7
    MA
    Mayes Patrick AEVP & Chief Scientific Officer
    INCYINCYTE CORP
    Open-market sale · 10b5-1 plan
    		SELL$274K
    2,207 sh
    		Aug 5, 2026Aug 7, 2026
    traded Aug 5, 2026
    		+2dSEC FORM 4

    Evidence

    11
    TT
    Tray ThomasPrincipal Accounting Officer
    INCYINCYTE CORP
    Tax withholding
    		F$56K
    477 sh
    		Jul 2, 2026Jul 7, 2026
    traded Jul 2, 2026
    		+5dSEC FORM 4

    Evidence

    11
    MA
    Mayes Patrick AEVP & Chief Scientific Officer
    INCYINCYTE CORP
    Tax withholding
    		F$41K
    350 sh
    		Jul 2, 2026Jul 7, 2026
    traded Jul 2, 2026
    		+5dSEC FORM 4

    Evidence

    2
    TT
    Tray ThomasPrincipal Accounting Officer
    INCYINCYTE CORP
    Option exercise · 10b5-1 plan
    		M$221K
    2,639 sh
    		Jun 4, 2026Jun 8, 2026
    traded Jun 4, 2026
    		+4dSEC FORM 4

    Evidence

    11
    TT
    Tray ThomasPrincipal Accounting Officer
    INCYINCYTE CORP
    Open-market sale · 10b5-1 plan
    		SELL$264K
    2,639 sh
    		Jun 4, 2026Jun 8, 2026
    traded Jun 4, 2026
    		+4dSEC FORM 4

    Evidence

    0
    TT
    Tray ThomasPrincipal Accounting Officer
    INCYINCYTE CORP
    Option exercise · 10b5-1 plan
    		M—
    2,639 sh
    		Jun 4, 2026Jun 8, 2026
    traded Jun 4, 2026
    		+4dSEC FORM 4

    Evidence

    8
    TT
    Tray ThomasPrincipal Accounting Officer
    INCYINCYTE CORP
    Open-market sale · 10b5-1 plan
    		SELL$200K
    2,051 sh
    		May 26, 2026May 28, 2026
    traded May 26, 2026
    		+2dSEC FORM 4

    Evidence

    9
    TM
    Trotta MatteoEVP, GM, Dermatology US
    INCYINCYTE CORP
    Tax withholding
    		F$50K
    537 sh
    		Mar 25, 2026Mar 26, 2026
    traded Mar 25, 2026
    		+1dSEC FORM 4

    Evidence

    5
    HL
    Heeson LeeEVP, Head of Incyte Intl
    INCYINCYTE CORP
    Tax withholding
    		F$11K
    111 sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    11
    IK
    Issa Mohamed KhairieEVP, Head of US Oncology
    INCYINCYTE CORP
    Grant or award
    		A—
    14.2K sh
    		Jan 16, 2026Jan 21, 2026
    traded Jan 16, 2026
    		+5dSEC FORM 4

    Evidence

    11
    MA
    Mayes Patrick AEVP & Chief Scientific Officer
    INCYINCYTE CORP
    Grant or award
    		A—
    4,218 sh
    		Jan 16, 2026Jan 21, 2026
    traded Jan 16, 2026
    		+5dSEC FORM 4

    Evidence

    19
    MJ
    Morrissey Michael JamesEVP, Head of Tech. Operations
    INCYINCYTE CORP
    Grant or award
    		A—
    7,426 sh
    		Jan 16, 2026Jan 21, 2026
    traded Jan 16, 2026
    		+5dSEC FORM 4

    Evidence

    5
    MJ
    Morrissey Michael JamesEVP, Head of Tech. Operations
    INCYINCYTE CORP
    Tax withholding
    		F$44K
    429 sh
    		Jan 20, 2026Jan 21, 2026
    traded Jan 20, 2026
    		+1dSEC FORM 4

    Evidence

    19
    HL
    Heeson LeeEVP, Head of Incyte Intl
    INCYINCYTE CORP
    Grant or award
    		A—
    8,911 sh
    		Jan 16, 2026Jan 21, 2026
    traded Jan 16, 2026
    		+5dSEC FORM 4

    Evidence

    11
    TT
    Tray ThomasPrincipal Accounting Officer
    INCYINCYTE CORP
    Grant or award
    		A—
    2,425 sh
    		Jan 16, 2026Jan 21, 2026
    traded Jan 16, 2026
    		+5dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001673776-25-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 5, 2025
    Published
    Nov 7, 2025
    Ingested by INSIDER
    Nov 5, 04:34 UTC
    Last re-read
    Nov 5, 04:34 UTC

    Extracted facts

    Filer
    Stein Steven H
    Role
    EVP & Chief Medical Officer
    Transaction
    Option exerciseAs filed: “M”
    Asset
    INCYTE CORP
    Ticker
    INCY
    Shares
    1,044
    Price per share
    $95.76
    Value
    $99,973
    Execution date (reported)
    Nov 5, 2025
    Owned after transaction
    108.1K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 1,044
    • Price: $95.76

    = $99,973

    What this establishes

    Stein Steven H filed this Form 4 reporting a option exercise of INCY on Nov 5, 2025. It became public on Nov 7, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    EVP & Chief Medical Officer
    Stein Steven Hcik:0001673776
    Issuer
    INCYTE CORPcik:0000879169

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.